SUSMED is a company that provides sustainable medical services to society, centered on the use of ICT, and aims to grow as a research and development-focused venture through its work primarily in DTx development. In June 2026, it began sales of Medcle, an app for insomnia disorders.
SUSMED is a research and development-focused venture whose mission is to continue providing sustainable medical services to society through the use of ICT. It is developing DTx as a third treatment modality after pharmaceuticals and medical devices, while seeking to improve the efficiency of the pharmaceutical industry’s value chain. The company name is derived from “SUStainable MEDicine,” and its head office is located at 1 Nihombashi-Honcho, Chuo-ku, Tokyo.
The company was listed on the Tokyo Stock Exchange Mothers market in 2021 and subsequently moved to the Tokyo Stock Exchange Growth Market following the market restructuring in 2022. After providing clinical trial support, DTx development support and automated machine-learning analysis systems, it began sales of Medcle, an app for sleep disorders, in June 2026.
As of August 2026, the company had 51 employees. Total assets at the end of the fiscal year ended June 2026 were ¥4,218 million, net assets were ¥4,070 million, the equity ratio was 94.2%, and the number of issued shares was 16,868,100, including treasury shares.
The head office relocation was carried out effective 14 September 2026. Future business development is expected to include the wider adoption of DTx, including in the field of insomnia disorders, and the expansion of clinical development support.